KPV — the tripeptide Lys-Pro-Val — is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid neuropeptide derived from the proopiomelanocortin (POMC) precursor protein. While alpha-MSH itself has been studied for decades in the context of pigmentation, appetite regulation, and inflammation, KPV represents a minimal active fragment that retains anti-inflammatory properties while lacking the full receptor binding profile of the parent peptide.

The primary research interest in KPV centers on its effects in gut epithelial biology. Multiple in vitro studies have examined KPV's ability to modulate the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, which is a central regulator of inflammatory gene expression in intestinal epithelial cells. Research has shown that KPV can inhibit the nuclear translocation of NF-κB subunits in stimulated colonocyte models, reducing the expression of downstream inflammatory mediators including IL-6, IL-8, and TNF-α.

Unlike full-length alpha-MSH, which activates melanocortin receptors (MC1R through MC5R) with broad systemic effects, KPV's receptor binding profile is more restricted. Research suggests that KPV may exert some of its effects through direct intracellular mechanisms rather than exclusively through surface receptor binding, which has implications for understanding how it might be delivered and how it interacts with the gut epithelial barrier.

The compound's nomination to the FDA's 503A Bulks List — reviewed at the July 23–24, 2026 PCAC meeting — was based primarily on its potential application in inflammatory bowel disease research. The PCAC voted 8–6 to recommend KPV’s inclusion alongside BPC-157 and TB-500, reflecting the panel's assessment that the existing preclinical evidence base supports further investigation in a regulated compounding context.

The renewed regulatory attention on KPV following the July 2026 vote has increased search volume and research interest in this compound substantially. For researchers studying gut epithelial inflammation, intestinal barrier function, or the melanocortin system, KPV represents a well-characterized tool compound with a growing literature base.

All compounds discussed are for laboratory research use only and are not intended for human or animal consumption.